SCHEMBL30777092

SCHEMBL30777092

CCOc1cccc(-c2ccc3c(=O)n(-c4ccccn4)ncc3c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 1/20 0.51
▸ IRAK4 Q9NWZ3 2/20 0.45
▸ FGFR1 P11362 1/20 0.42
▸ FGFR2 P21802 1/20 0.42
▸ FGFR3 P22607 1/20 0.42
▸ CYP19A1 P11511 1/20 0.42
▸ CYP11B1 P15538 1/20 0.42
▸ CYP11B2 P19099 1/20 0.42
▸ TP53 P04637 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PTGS2 P35354 1/20 0.41
▸ FFAR4 Q5NUL3 3/20 0.41
▸ RXRA P19793 1/20 0.40
▸ RXRB P28702 1/20 0.40
▸ GRM7 Q14831 1/20 0.40
▸ HTR3A P46098 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ BACE1 P56817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29175794 1.00 NR3C1 (0.51) NR3C1IRAK4FGFR1FGFR2FGFR3
SCHEMBL29175756 0.89 GRM7 (0.50) IRAK4GRM7HPGDROCK2L3MBTL1
SCHEMBL30777031 0.89 GRM7 (0.50) IRAK4GRM7HPGDROCK2L3MBTL1
SCHEMBL29175764 0.84 IRAK4 (0.44) NR3C1IRAK4FFAR4GRM7HTR3A
SCHEMBL30777057 0.84 IRAK4 (0.44) NR3C1IRAK4FFAR4GRM7HTR3A
SCHEMBL30777029 0.83 GRM7 (0.49) IRAK4FFAR4GRM7HTR3AHPGD
SCHEMBL29175817 0.83 GRM7 (0.49) IRAK4FFAR4GRM7HTR3AHPGD
SCHEMBL29175821 0.82 IRAK4 (0.44) IRAK4FFAR4GRM7BACE1ROCK2
SCHEMBL30777052 0.82 IRAK4 (0.44) IRAK4FFAR4GRM7BACE1ROCK2
SCHEMBL30777037 0.80 NR3C1 (0.51) NR3C1FGFR1FGFR2FGFR3CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327375-A1 SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR ADDEX PHARMA S.A. (CH) 2024-10-03 — — US disclosed
EP-4337643-A1 SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR Addex Pharma S.A (CH) 2024-03-20 — — EP disclosed
CN-117597331-A Substituted heterobicyclic derivatives as MGLU7 receptor negative allosteric modulators 阿德克斯法尔马股份公司 2024-02-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327375-A1 SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR GRM7, GRM2, GRM1 NR3C1 212/4885IRAK4 1141/4885FGFR1 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback